Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Cantor Fitzgerald
Julphar
Cipla
Queensland Health
Daiichi Sankyo
Federal Trade Commission
Harvard Business School

Generated: December 10, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021029

« Back to Dashboard

NDA 021029 describes TEMODAR, which is a drug marketed by Merck Sharp Dohme and is included in two NDAs. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TEMODAR profile page.

The generic ingredient in TEMODAR is temozolomide. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the temozolomide profile page.
Summary for 021029
Tradename:TEMODAR
Applicant:Merck Sharp Dohme
Ingredient:temozolomide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021029
Mechanism of ActionAlkylating Activity
Suppliers and Packaging for NDA: 021029
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TEMODAR temozolomide CAPSULE;ORAL 021029 NDA Merck Sharp & Dohme Corp. 0085-1366 0085-1366-03 5 PACKET in 1 CARTON (0085-1366-03) > 1 CAPSULE in 1 PACKET (0085-1366-05)
TEMODAR temozolomide CAPSULE;ORAL 021029 NDA Merck Sharp & Dohme Corp. 0085-1366 0085-1366-04 14 PACKET in 1 CARTON (0085-1366-04) > 1 CAPSULE in 1 PACKET (0085-1366-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Aug 11, 1999TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength20MG
Approval Date:Aug 11, 1999TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Aug 11, 1999TE:ABRLD:Yes

Expired US Patents for NDA 021029

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme TEMODAR temozolomide CAPSULE;ORAL 021029-001 Aug 11, 1999 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme TEMODAR temozolomide CAPSULE;ORAL 021029-004 Aug 11, 1999 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme TEMODAR temozolomide CAPSULE;ORAL 021029-005 Oct 19, 2006 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Teva
Moodys
Mallinckrodt
Citi
Chinese Patent Office
McKesson
Cantor Fitzgerald
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.